赖诺普利对PCOS大鼠病理生理及PAI-1浓度的影响
本研究在来曲唑诱导的PCOS大鼠模型中探讨赖诺普利对PAI-1浓度及卵巢形态功能的影响。结果显示赖诺普利降低卵巢重量和面积、囊性卵泡数量及壁厚度、血清LH和睾酮浓度,并改变循环PAI-1水平,妊娠率在PCOS组为0%、赖诺普利组为16.7%。
要点
- 赖诺普利降低PCOS大鼠卵巢重量、囊性卵泡数量及血清LH和睾酮。
- 三组循环PAI-1浓度分别为7.7±0.9、9.8±0.7和8.6±0.7 ng/ml(P<0.001)。
- 妊娠率对照组100%、PCOS组0%、赖诺普利组16.7%。
核心结论
- 在来曲唑诱导的PCOS大鼠模型中,赖诺普利可能通过抑制全身和卵巢PAI-1产生而改变来曲唑的作用。
研究设计与样本
- 前瞻性随机对照动物研究,使用雌性Wistar白化大鼠,对照组12只,研究组48只用来曲唑造模9周。
- 确认动情周期紊乱后,研究组随机分为来曲唑组(n=24)和来曲唑+赖诺普利15 mg/kg每日组(n=24),12周后每组再随机分亚组进行生化、组织病理和免疫组化分析及受精率研究。
主要发现
- 与来曲唑组相比,赖诺普利组卵巢重量和面积、囊性卵泡数量和壁厚度、血清LH和睾酮浓度均降低(P<0.001)。
- 三组循环PAI-1浓度分别为7.7±0.9 ng/ml、9.8±0.7 ng/ml和8.6±0.7 ng/ml(P<0.001)。
- 妊娠率在对照组为100%、来曲唑组为0%、赖诺普利组为16.7%。
临床怎么用
- 动物实验提示PAI-1抑制剂可能改善PCOS相关卵巢病理和生育结局,但尚未支持临床常规使用。
局限性
- 本研究为动物模型研究,结论不能直接外推至人类PCOS患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Angiotensin-converting enzyme inhibition results in a significant reduction in plasma concentrations of plasminogen activator inhibitor-1 (PAI-1). What are the effects of lisinopril treatment on PAI-1 concentrations and the morphology and function of the ovaries in the letrozole-induced polycystic ovary syndrome (PCOS) rat model? DESIGN: This prospective randomized controlled animal study involved female Wistar albino rats. Twelve rats were assigned as controls (group I). In the study group (n = 48), letrozole (an aromatase inhibitor) was administered for PCOS modelling for 9 weeks. After confirming disrupted oestrous cycles, the study group was randomized into two groups: group II (n = 24; letrozole only) and group III (n = 24; letrozole + lisinopril 15 mg/kg per day). After 12 weeks, each group was divided randomly into two. Biochemical, histopathological and immunohistochemical analyses was performed in subgroups designated A, and fertilization rates were studied in subgroups designated B. RESULTS: Lisinopril treatment reduced the weight and area of the ovaries, the number and wall thickness of cystic follicles, and serum concentrations of LH and testosterone, relative to group II (P < 0.001). Circulating PAI-1 concentrations were significantly different among three groups (7.7 ± 0.9 ng/ml, 9.8 ± 0.7 ng/ml and 8.6 ± 0.7 ng/ml for groups IA, IIA and IIIA; P < 0.001). Pregnancy rates were 100%, 0% and 16.7% in groups IB, IIB and IIIB. CONCLUSIONS: In the letrozole-induced rodent PCOS model, lisinopril modifies the action of letrozole, possibly by inhibition of systemic and ovarian production of PAI-1. The use of PAI-1 inhibitors deserves further investigation in understanding the pathogenesis of PCOS.
引用
- Coskun B, Ercan CM, Togrul C, et al. Effects of lisinopril treatment on the pathophysiology of PCOS and plasminogen activator inhibitor-1 concentrations in rats. Reprod Biomed Online. 2020. PMID: 34756399. doi:10.1016/j.rbmo.2020.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。